Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Faron Pharmaceuticals Oy

FARN.L ✗ NOT COMPLIANTFree checks used up today ☆ Track — members

LSE · Healthcare · Biotechnology & Medical Research ·

UK Micro Cap Analyst: BUY

Last Close

$0.42

▲ +0.00%

Market Cap $87.12M · Vol 1.06K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$87.12M

Micro Cap

Div Yield

N/A

Annual dividend

EPS Growth

+51.86%

YoY

RSI (14)

0.00

Momentum

Beta

1.41

vs Market

52W High

$2.59

83.39% below

52W Low

$0.40

5.42% above

Volume

1.06K

Avg 36.46K

P/B

N/A

Price-to-book

ROE

239.00%

Return on equity

Free Float

84.11%

Public shares

Shariah Compliance8 STANDARDS

✗ Faron Pharmaceuticals Oy (FARN.L) stock is currently not Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does FARN.L pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-1.56%

-13.70%

-25.00%

-24.10%

YTD

-81.01%

-83.12%

-82.52%

-87.90%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-32,013,201.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	239.00%
ROA · ROIC	-183.58% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	N/A
P/FCF	N/A
EPS Growth	+51.86%
Outstanding Shares	206.54M

Technical Indicators

50-Day SMA	$0.48
200-Day SMA	$0.65
RSI (14)	0.00
Beta	1.41
52-Week High	$2.59
52-Week Low	$0.40

Volume Today	1.06K
Avg Daily Volume (30D)	36.46K
Relative Volume	0.03x
Volatility (10D)	23.53
Volatility (30D)	41.44
Free Float	84.11%

Analyst Consensus

BUY

Current Price $0.42

Mean Target $3.18

52W Low$0.40 52W High$2.59

Current

Target

$0.40 $2.59

Current Analyst target

+653.47% upside potential · 3 analysts

Identifiers

ExchangeLSE

FIGIBBG008R5TCG6

ISINFI4000153309

CountryFinland

Sub-IndustryBio Therapeutic Drugs

Earnings DateMar 2, 2027

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co., Ltd. -2.22% ARGX.BR argenx SE -2.87% ARGX argenx SE -2.00% GMAB.CO Genmab A/S -5.47% GMAB Genmab A/S -3.75%

Company Profile

Faron Pharmaceuticals Oy is a Finland-based clinical stage biopharmaceutical company. The company has three drug candidates all based on mastering immune modulation and, as a result, tackling unmet needs in cancer, preventing organ damage and treating blood count abnormalities. The Company's goal is to build future immunotherapy, i.e., to bring new treatments to patients by affecting the immune system. Faron’s drug candidate, Traumakine, is a drug developed by the Company to prevent multi-organ damage and excessive inflammatory responses. Another drug candidate, Haematokine, promotes the expansion of bone marrow stem cells. It is being developed, e.g., for the treatment of chemotherapyinduced neutropenia (CIN). In neutropenia patients have less blood cells called neutrophils than normal due to cancer treatment.